Skip to content
TrialScanner

NCT05286762

Phase 3 Efficacy and Safety Fixed-Dose Study in Pediatrics (6-17) With ADHD Using CTx-1301

Phase 3CompletedCINGLead

Registry record

Lead sponsor
Cingulate Therapeutics
Conditions
ADHD; Attention Deficit Hyperactivity Disorder; ADHD - Combined Type; Attention Deficit Hyperactivity Disorder Combined; Attention-deficit Hyperactivity
Primary completion
Feb 29, 2024Actual
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Open NCT05286762 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.